AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02042690
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
Trial: NCT00147251
Drug: FDA approved drugs to treat blood pressure and cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02126371
Drug: LEO32731
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03771053
Drug: Ezetimibe with simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
Trial: NCT03771053
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40mg everyday for 12 months after PCI
Trial: NCT00267189
Drug: Calcineurin inhibitors (CNI)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02608320
Drug: Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Trial: NCT00267189
Drug: Mycophenolate acid (MPA)/ Azathioprine (AZA)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00267189
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01439568
Drug: LY2510924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous injection
Trial: NCT02608320
Drug: New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Trial: NCT00003254
Drug: ethynyluracil
RxNorm normalized name: 5-Ethynyluracil
DrugBank: Eniluracil (DB03516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/m2/dose, PO, Days 1-28, q 5wk
Trial: NCT00003254
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
Trial: NCT01632137
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill one drop into each eye 4 times a day for 4 weeks.
Trial: NCT01062048
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea administered in general use according to the local label
Trial: NCT03282851
Drug: MSB11456
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single injection of MSB11456 on Day 1.
Trial: NCT00760448
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03970213
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline given during surgery
Trial: NCT03773211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
Trial: NCT02098824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of capsule containing placebo
Trial: NCT03843112
Drug: Vivag Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains two lactobacilli strains; l. gasseri and l. rhamnosus
Trial: NCT03843112
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal supplements
Trial: NCT03090009
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg twice a day for 14 days
Trial: NCT03090009
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo group
Trial: NCT00629772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
Trial: NCT03135626
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03135626
Drug: MTA Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02415257
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
Trial: NCT00917111
Drug: Nasal CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times a day for 14 days
Trial: NCT00917111
Drug: Inactive Placebo Gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02839356
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
Trial: NCT02839356
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mL irrigation with physiological saline over the entire papilla
Trial: NCT03359239
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.19 mL
Trial: NCT01131767
Drug: Naproxen Sodium & Pseudoephedrine HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Trial: NCT00253760
Drug: dietary amino acids; cysteine and methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070655
Drug: vitamin K antagonist (warfarin or acenocoumarol) tablets
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00186329
Drug: Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02570841
Drug: Topical Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo exposure within an area of 3x3 cm for 60 minutes
Trial: NCT01263704
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
Trial: NCT03866187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Trial: NCT02448628
Drug: CS-3150
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00445978
Drug: Sapropterin Dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
Trial: NCT01502280
Drug: Placebo - ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
Trial: NCT04568993
Drug: Volar to the MCP-joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint
Trial: NCT04068610
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of FOLFOX (5-FU, oxaliplatin, and folinic acid) as stated in arm description.
Trial: NCT01163266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine placebo-matching capsules
Trial: NCT00565370
Drug: Capecitabine, Cisplatin, Sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
Trial: NCT02752204
Drug: AZD 2014
RxNorm normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
Trial: NCT01712230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00773526
Drug: RO5126766
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
Trial: NCT00647166
Drug: corticosteroid and azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
Trial: NCT03295058
Drug: Non ATG Conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
Trial: NCT03295058
Drug: ATG conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the other 50% of the patients will receive Cyclophosphamide + ATG
Trial: NCT04399837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT03472872
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
Trial: NCT03472872
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000mg acetaminophen IVPB
Trial: NCT02182258
Drug: BIBF 1120 intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182258
Drug: Placebo ampoule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04192617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 600 mg intravenous (IV)
Trial: NCT04192617
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate: 7.5-20 mg/week oral
Trial: NCT04060849
Drug: Nozin
RxNorm normalized name: Nozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via nasal single-use popswabs or single-use cotton tipped applicators
Trial: NCT04525157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01457131
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
Trial: NCT01604382
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Anesthesia as described above
Trial: NCT01604382
Drug: Neuraxial anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuraxial anesthesia as described above
Trial: NCT02931565
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03437460
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
Trial: NCT00767689
Drug: Vitamin B 6
RxNorm normalized name: vitamin B 6 100 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin b6 100 mg po daily
Trial: NCT00767689
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo is given in the placebo arm
Trial: NCT03406689
Drug: Nepafenac 0.1% Oph Susp
RxNorm normalized name: NEPAFENAC 0.1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
Trial: NCT03406689
Drug: Nepafenac 0.3% Oph Susp
RxNorm normalized name: NEPAFENAC 0.3% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
Trial: NCT04158830
Drug: Aspirin 81 mg Enteric Coated Tab - 1 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take one (1) 81 mg tablet each evening
Trial: NCT04158830
Drug: Aspirin 81 mg Enteric Coated Tab - 2 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take two (2) 81 mg tablets each evening
Trial: NCT01927341
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID
Trial: NCT02801448
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrine-based placebo without sulforaphane
Trial: NCT02547363
Drug: LEO 43204 gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02616419
Drug: Maxilene® (Lidocaine liposomal 4%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
Trial: NCT02547363
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02921360
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00413764
Drug: estradiol-norethisterone
RxNorm normalized name: ethinyl estradiol / ethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
Trial: NCT00315536
Drug: Administration of remifentanil and glycopyrrolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg, intravenius use
Trial: NCT03409679
Drug: Two anti-pseudomonal antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Trial: NCT01273779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
Trial: NCT04643821
Drug: N-acetylcysteine, NAC, and calcitriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv administration of antioxidant and active vitamin D
Trial: NCT03627767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as two tablets to be taken orally once daily for 40 weeks
Trial: NCT01550471
Drug: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
Trial: NCT01550471
Drug: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
Trial: NCT01550471
Drug: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
Trial: NCT01550471
Drug: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
Trial: NCT01550471
Drug: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
Trial: NCT01550471
Drug: Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
Trial: NCT00518973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
Trial: NCT02360111
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01933217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00027937
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00316771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po bid
Trial: NCT01588639
Drug: Insulin (Scilin R _BAY81-9924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
Trial: NCT04340297
Drug: Acid inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
Trial: NCT04340297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
Trial: NCT03781544
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
Trial: NCT03173027
Drug: Fangji Huangqi pill or Fangji Huangqi pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
Trial: NCT01417936
Drug: Sym004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
Trial: NCT01843088
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
Trial: NCT04547049
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.8 g/m2/day administered IV day -5 through -4.